Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
1(5%)
Results Posted
62%(8 trials)
Terminated
3(16%)

Phase Distribution

Ph phase_3
4
21%
Ph phase_1
4
21%
Ph phase_2
2
11%
Ph phase_4
7
37%
Ph not_applicable
1
5%

Phase Distribution

4

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
4(22.2%)
Phase 2Efficacy & side effects
2(11.1%)
Phase 3Large-scale testing
4(22.2%)
Phase 4Post-market surveillance
7(38.9%)
N/ANon-phased studies
1(5.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.2%

13 of 18 finished

Non-Completion Rate

27.8%

5 ended early

Currently Active

1

trials recruiting

Total Trials

19

all time

Status Distribution
Active(1)
Completed(13)
Terminated(5)

Detailed Status

Completed13
Terminated3
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
1
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (22.2%)
Phase 22 (11.1%)
Phase 34 (22.2%)
Phase 47 (38.9%)
N/A1 (5.6%)

Trials by Status

recruiting15%
completed1368%
terminated316%
withdrawn211%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT06162377Phase 4

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Recruiting
NCT02977286Phase 4

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Terminated
NCT03852524Phase 2

Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention

Completed
NCT00936884Phase 3

Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Completed
NCT00858754Phase 4

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Withdrawn
NCT01366365Phase 1

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

Completed
NCT01366378Phase 1

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Completed
NCT01186770Phase 3

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Completed
NCT01368562Not Applicable

Compassionate Use Study of Methylnaltrexone

Completed
NCT00401375Phase 3

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

Completed
NCT01955213

Methylnaltrexone for Opioid Induced Constipation

Terminated
NCT00672477Phase 4

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Completed
NCT02403830Phase 4

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

Completed
NCT01889290Phase 1

Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients

Completed
NCT01773096Phase 4

Methylnaltrexone Use for Opioid-induced Postoperative Constipation

Completed
NCT01360372Phase 3

Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates

Withdrawn
NCT01596764Phase 1

Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.

Completed
NCT01012960Phase 4

Opioids and Esophageal Function

Completed
NCT01117376Phase 2

Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients

Terminated

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19